Could COVID expand the future of addiction research? Long-term implications in the pandemic era.

"DECLARATION OF INTERESTS A.E. has been employed by KCL to work on GW Pharma supported studies. He has received speakers fee and travel grant from GW Pharma and speakers fee from Lundbeck Pharma. A.E. is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and the Maudsley National Health Service (NHS) Foundation Trust and King's College London. S.S. is supported by the NIHR Biomedical Research Centre for Mental Health at South London and the Maudsley NHS Foundation Trust and King's College London, the Society for the Study of Addiction and the King's Prize Fellowship Scheme, Wellcome Trust Institutional Strategic Support Fund. B.T. is supported by the NIHR Biomedical Research Centre for Mental Health at South London and the Maudsley NHS Foundation Trust and King's College London. J.S. is a researcher and clinician who has worked with a range of governmental and non‐governmental organisations, and with pharmaceutical companies to seek to identify new or improved treatments from whom his employer (King's College London) has received honoraria, travel costs and/or consultancy payments: this includes, last 3 years, MundiPharma, Camurus and Accord and trial medication supply from Camurus. J.S.'s research is supported by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King's College London. J.S. is an NIHR Senior Investigator. For a fuller account, see at http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx."

"Funding information None."